Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 31.35 is 65% above its 5-year average of 19.05, near the high end of its 5-year range (5.71–34.33).
As of the fiscal period ended Tuesday, June 30, 2026. 15.95% above its 12-month average of 27.04.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 31.35.
CURRENT RATIO
31.35
CURRENT RATIO AVG TTM
27.04
CURRENT RATIO AVG 3Y
23.30
CURRENT RATIO AVG 5Y
19.05
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+15.95%
CURRENT VS 3Y AVG
+34.55%
CURRENT VS 5Y AVG
+64.56%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+736.02%
vs the sector median at left
Fulcrum Therapeutics, Inc.
Market Cap
$281.92M
Current Ratio
31.35
TTM Avg
27.04
3Y Avg
23.30
5Y Avg
19.05
Market Cap
$287.63M
Current Ratio
19.48
TTM Avg
1.73
3Y Avg
4.11
5Y Avg
4.35
Market Cap
$283.58M
Current Ratio
4.69
TTM Avg
11.27
3Y Avg
11.27
5Y Avg
11.27
Market Cap
$285.88M
Current Ratio
6.63
TTM Avg
6.50
3Y Avg
6.00
5Y Avg
4.95
Market Cap
$286.98M
Current Ratio
45.02
TTM Avg
28.56
3Y Avg
20.10
5Y Avg
23.41
Market Cap
$271.28M
Current Ratio
9.24
TTM Avg
7.84
3Y Avg
8.19
5Y Avg
10.90
Market Cap
$271.00M
Current Ratio
4.85
TTM Avg
6.69
3Y Avg
6.56
5Y Avg
6.64
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $281.92M | 31.35 | 27.04 | 23.30 | 19.05 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $287.63M | 19.48 | 1.73 | 4.11 | 4.35 |
| Aurora Cannabis Inc. (ACB)vs › | $282.77M | 5.36 | 5.13 | 3.92 | 3.90 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $283.58M | 4.69 | 11.27 | 11.27 | 11.27 |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.88M | 6.63 | 6.50 | 6.00 | 4.95 |
| Sagimet Biosciences Inc. (SGMT)vs › | $286.98M | 45.02 | 28.56 | 20.10 | 23.41 |
| Standard BioTools Inc. (LAB)vs › | $287.29M | 9.10 | 4.95 | 4.04 | 3.29 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.28M | 9.24 | 7.84 | 8.19 | 10.90 |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | 4.85 | 6.69 | 6.56 | 6.64 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $292.98M | 4.70 | 5.10 | 7.75 | 8.34 |
Current Ratio
31.35
Quick Ratio
31.35
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 31.35 |
| 2026-03-31 | 34.33 |
| 2025-12-31 | 27.40 |
| 2025-09-30 | 17.70 |
| 2025-06-30 | 24.42 |
| 2025-03-31 | 28.71 |
| 2024-12-31 | 22.63 |
| 2024-09-30 | 18.44 |
| 2024-06-30 | 22.07 |
| 2024-03-31 | 20.38 |
| 2023-12-31 | 17.71 |
| 2023-09-30 | 18.65 |
| 2023-06-30 | 19.11 |
| 2023-03-31 | 21.02 |
| 2022-12-31 | 12.41 |
| 2022-09-30 | 15.49 |
| 2022-06-30 | 7.88 |
| 2022-03-31 | 10.94 |
| 2021-12-31 | 11.77 |
| 2021-09-30 | 11.95 |
| 2021-06-30 | 5.71 |
| 2021-03-31 | 6.49 |
| 2020-12-31 | 4.23 |
| 2020-09-30 | 4.99 |
| 2020-06-30 | 9.67 |
| 2020-03-31 | 5.95 |
| 2019-12-31 | 8.24 |
| 2019-09-30 | 12.26 |
| 2019-06-30 | 8.10 |
| 2019-03-31 | 13.65 |
| 2018-12-31 | 17.52 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
